ArticleInternal and emergency medicine2021
Serial KL-6 measurements in COVID-19 patients.
Article in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.Virology · 2022Pooled it
- Combined use of serum KL-6 and respiratory functional parameters for identifying fibrotic lung damage in SARS-CoV-2-induced interstitial pneumonia.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Novel Biomarkers for SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2025Review
- Krebs von den Lungen-6 (KL-6) as a diagnostic and prognostic biomarker for non-neoplastic lung diseases.Clinical chemistry and laboratory medicine · 2025Article
- Initial and peak serum levels of Krebs von den Lungen-6 for predicting the prognosis of patients with COVID-19.The Korean journal of internal medicine · 2025Article
- SARS-CoV-2 and Dysphagia: A Retrospective Analysis of COVID-19 Patients with Swallowing Disorders.Dysphagia · 2025Article
- Eight-fold increased COVID-19 mortality in autosomal dominant tubulointerstitial kidney disease due to MUC1 mutations: an observational study.BMC nephrology · 2024Observational
- Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19.Infectious diseases & clinical microbiology · 2023Article
- Predictive Model for Mortality in Severe COVID-19 Patients across the Six Pandemic Waves.Viruses · 2023Article
- Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia.Journal of clinical medicine · 2023Article
- Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19.Journal of clinical medicine · 2023Article
- MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients.Biomedicines · 2023Article
- Autophagy in Inflammatory Response against SARS-CoV-2.International journal of molecular sciences · 2023Review
- KL-6 levels in the connective tissue disease population: typical values and potential confounders-a retrospective, real-world study.Frontiers in immunology · 2023Article
- Long-term respiratory follow-up of ICU hospitalized COVID-19 patients: Prospective cohort study.PloS one · 2023Article
- Mortality predictors in patients with COVID-19 pneumonia: a machine learning approach using eXtreme Gradient Boosting model.Internal and emergency medicine · 2022Article
- Usefulness of KL-6 for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2022Article
- Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression.Journal of pharmacological sciences · 2022Article
- Peak value of serum KL-6 may be useful for predicting poor prognosis of severe COVID-19 patients.European journal of medical research · 2022Observational
- Surfactant protein D: A useful biomarker for distinguishing COVID-19 pneumonia from COVID-19 pneumonia-like diseases.Health science reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV2-induced direct cytopathic effects against type II pneumocytes are suspected to play a role in mediating and perpetuating lung damage. The aim of this study was to evaluate serum KL-6 behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty patients (median age IQR, 65 (52-69), 43 males), hospitalized for COVID-19 at Siena COVID Unit University Hospital, were prospectively enrolled. Twenty-six patients were selected (median age IQR, 63 (55-71), 16 males); all of them underwent follow-up evaluations, including clinical, radiological, functional, and serum KL-6 assessments, after 6 (t1) and 9 (t2) months from hospital discharge. At t0, KL-6 concentrations were significantly higher than those at t1 (760 (311-1218) vs. 309 (210-408) p = 0.0208) and t2 (760 (311-1218) vs 324 (279-458), p = 0.0365). At t0, KL-6 concentrations were increased in patients with fibrotic lung alterations than in non-fibrotic group (755 (370-1023) vs. 305 (225-608), p = 0.0225). Area under the receiver operating curve (AUROC) analysis showed that basal KL-6 levels showed good accuracy in discriminating patients with fibrotic sequelae radiologically documented (AUC 85%, p = 0.0404). KL-6 concentrations in patients with fibrotic involvement were significantly reduced at t1 (755 (370-1023) vs. 290 (197-521), p = 0.0366) and t2 (755 (370-1023) vs. 318 (173-435), p = 0.0490). Serum concentrations of KL-6 in hospitalized COVID-19 patients may contribute to identify severe patients requiring mechanical ventilation and to predict those who will develop pulmonary fibrotic sequelae in the follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.